Circulating tumor cells and PET

Journal of Nuclear Medicine

Volumn 52, Issue 10, 2011, Pages 1501-1504

  Yu, Jian Q ^a   Cristofanilli, Massimo ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Blood biomarkers; Circulating tumor cells; PET imaging

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; HORMONE RECEPTOR; TUMOR MARKER;

APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER STEM CELL; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; LIVER METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOACTIVITY; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 80053466551     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.097683     Document Type: Review

References (26)

1. Gambhir SS. Just what is molecular imaging? MI Gateway. SNM Web site. Available at: http://interactive.snm.org/docs/MICOE%20Newsletter-2007-1-web.pdf. Accessed August 31, 2011.
2. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360:626-633.
3. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30:908-917.
4. Apisarnthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H- fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590-4597. (Pubitemid 44297809)
5. 18F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy: a clinical application model of esophageal cancer. Semin Oncol. 2007;34(suppl 1)S31-S36.
6. Graf N, Herrmann K, den Hollander J, et al. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol. 2008;10:349-355.
7. 18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging. 2009;36:209-218.
8. 18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51.
9. 18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;75:101-108.
10. 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun. 2010;31:1016-1024.
11. 18F] HX4: a phase I trial. Eur J Nucl Med Mol Imaging. 2010;37:1663-1668.
12. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging. 2004;31:469-474.
13. 64Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging. 2007;34:247-258.
14. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
15. Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456-463.
16. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791. (Pubitemid 39095313)
17. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;2008:3213-3221.
18. De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-6309.
19. Mego M, Mani S, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer: clinical applications. Nature Rev Clin Oncol. 2010;7:693-701.
20. Reuben JM, Lee BN, Li C, et al. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J. 2010;16:327-330.
21. Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11:R46.
22. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer. 2008;113:2422-2430.
23. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging: predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403-6409. (Pubitemid 44799711)
24. 18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009;27:3303-3311.
25. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010;21:33-39.
26. 18F-FDG-PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 2010;51:1213-1218.